Off-label use of recombinant human factor VIIA

Annals of Thoracic Surgery

Volumn 98, Issue 2, 2014, Pages 393-395

  Goodnough, Lawrence Tim ^a   Levy, Jerrold H ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICAGRELOR; TRANEXAMIC ACID;

ADVERSE OUTCOME; COMORBIDITY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ERYTHROCYTE TRANSFUSION; FIBRINOLYTIC THERAPY; HEART SURGERY; HEMOPHILIA; HIGH RISK PATIENT; HUMAN; INFORMED CONSENT; MORTALITY; NEUROLOGICAL COMPLICATION; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OPERATING ROOM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELECTION BIAS; SURGICAL PATIENT; THROMBOCYTE ANOMALY; THROMBOEMBOLISM; THROMBOSIS;

CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; FEMALE; HUMANS; MALE; RECOMBINANT PROTEINS;

EID: 84905494589     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2014.06.007     Document Type: Editorial

References (16)

1. L.T. Goodnough, and A. Shander Current status of pharmacologic therapies in patient blood management Anesth Analg 116 2013 15 34
2. CRASH-2 collaborators1 I. Roberts, H. Shakur, and A. Afolabi et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial Lancet 377 2011 1096 1101
3. J.H. Levy Antifibrinolytic therapy: new data and new concepts Lancet 376 2010 3 4
4. A.C. Logan, V. Yank, and R.S. Stafford Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records Ann Intern Med 154 2011 516 522
5. A. Alfirevic, A. Duncan, J. You, C. Lober, and E. Soltesz Recombinant factor VII is associated with worse survival in complex cardiac surgical patients Ann Thorac Surg 98 2014 618 624
6. E. Simpson, Y. Lin, S. Stanworth, J. Birchall, C. Doree, and C. Hyde Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia Cochrane Database Syst Rev 3 2012 CD005011
7. Y. Lin, C.J. Moltzan, and D.R. Anderson The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework Transfus Med 22 2012 383 394
8. V.A. Ferraris, J.R. Brown, and G.J. Despotis et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines Ann Thorac Surg 91 2011 944 982
9. R. Gill, M. Herbertson, and A. Vuylsteke et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery Circulation 120 2009 21 27
10. L.T. Goodnough, D.M. Lublin, L. Zhang, G. Despotis, and C. Eby Transfusion medicine service policies for recombinant factor VIIa administration Transfusion 44 2004 1325 1331
11. A.Y. Sheikh, C.C. Hill, L.T. Goodnough, L.L. Leung, and M.P. Fischbein Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding Transfusion 54 2014 300 305
12. K. Karkouti, and J.H. Levy Recombinant activated factor VII: the controversial conundrum regarding its off-label use Anesth Analg 113 2011 711 712
13. M. Mazzeffi, F. Szlam, J.A. Jakubowski, K.A. Tanaka, A. Sugidachi, and J.H. Levy In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel Thromb Res 132 2013 106 111
14. F. Szlam, K.A. Tanaka, B. Rumph, D. Bolliger, and J.H. Levy In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition Thromb Haemost 103 2009 863 865
15. K. Karkouti, W.S. Beattie, and D.N. Wijeysundera et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis Transfusion 45 2005 26 34
16. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800